We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases

Sumaira Aasi, MD; Rona Silkiss, MD; Jean Y. Tang, MD, PhD; Ashley Wysong, MD; Andy Liu, BS; Ervin Epstein, MD; Anthony E. Oro, MD, PhD; Anne Lynn S. Chang, MD
JAMA Dermatol. 2013;149(2):242-243. doi:10.1001/jamadermatol.2013.1798.
Text Size: A A A
Published online


While keratoacanthomas (KAs) and squamous cell carcinomas (SCCs) have been reported in response to a number of systemic drugs such as vemurafenib, sorafenib, or voriconazole,13 their association with Smoothened inhibitors has not been previously noted. Herein, we report 2 cases of new KAs developing within 2 months of starting vismodegib therapy in individuals with no history of KAs or SCCs.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure. Development of distant keratoacanthomas (KAs) while undergoing vismodegib therapy. A, Clinical photograph of the rapid-onset 2-cm nodule on the right arm of patient 1 after 2 weeks of vismodegib treatment for an eyelid basal cell carcinoma (BCC). B, Histologic image from case 1 shows a cup-shaped, well-differentiated squamous cell carcinoma (SCC) invaginating into the dermis that was filled with keratin, consistent with KA (hematoxylin-eosin, original magnification ×100). C, Clinical photograph of KA development on the inferior medial brow of patient 2 after 7 weeks of vismodegib therapy for a periocular BCC. D, Histologic image shows a well-differentiated SCC, or KA (hematoxylin-eosin, original magnification ×100).




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

24 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections